All regulatory closing conditions related to Novo Holdings’ $16.5 billion acquisition of U.S. contract drug maker Catalent (NYSE: CTLT) had
1 year ago
BRUSSELS – On Friday, Novo Holdings gained unconditional EU antitrust approval for its $16.5 billion acquisition of U.S. contract drug
BRUSSELS/LONDON – Novo Holdings is set to gain unconditional EU antitrust approval for its planned $16.5 billion takeover of U.S.
BRUSSELS/LONDON – EU antitrust regulators have asked pharma rivals and customers for feedback in four business areas in light of
BRUSSELS/LONDON – EU antitrust regulators will decide by December 6 whether to clear Novo Holdings’ acquisition of contract drug manufacturer
FRANKFURT – The CEO of pharmaceuticals giant Roche said authorities should block the takeover of contract drug manufacturer Catalent (NYSE:
On Monday, Catalent (NYSE: CTLT) CEO Alessandro Maselli said he will remain at the helm of the U.S.-based contract drugmaker
NEW YORK – On Thursday, U.S. consumer groups and two large labor unions urged the U.S. Federal Trade Commission to
Catalent (NYSE: CTLT) has agreed to sell its oral drug development and small-scale manufacturing facility in Somerset, New Jersey to
NEW YORK – U.S. Senator Elizabeth Warren has asked antitrust regulators to scrutinize a $16.5 billion deal in which Novo
